// App-Quantinova.ai

TPS9110 : A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Lecia V. Sequist

Principal Investigators

  • Ian Churchill Anderson

  • Nathan Demars

  • Enriqueta Felip

  • Wael A. Harb

  • Rudolf M. Huber

  • Art J. Kudla

  • Jean Kyung Lee

  • Sara Mathews

  • Ty McClure

  • Jorge J. Nieva

  • Maurice Perol

  • Frances A. Shepherd

  • Alexander I. Spira

  • Akos Gabor Czibere

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • St Joseph Heritage Healthcare, Santa Rosa, CA

  • Merrimack, Cambridge, MA

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Horizon Oncology Center, Lafayette, IN

  • Medizinische Klinik Innenstadt, Munich, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Merrimack Pharmaceuticals, Cambridge, MA

  • University of Southern California, Los Angeles, CA

  • Leon-Berard Cancer Centre, Lyon, France

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

Locations

  • Canada

  • Spain

  • Germany

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Seribantumab

  • Pemetrexed

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • II

Study Id's

  • NCT02387216

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved